Wang, L., Zheng, Z., Li, R., Xu, P., Cheng, S., Zhao, W. L. (2025). A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis. Blood. https://doi.org/10.1182/blood-2025-7123